Symbiotec Pharmalab IPO GMP History
Symbiotec Pharmalab IPO has been listed on September 1, 2026 at a listing price of ₹988, against the issue price of ₹988 — a gain of ₹0 (+0%). The GMP peaked at ₹410 on 22 August 2026 and reached a low of ₹185 on 1 September 2026. The day-wise GMP trend below shows how grey market sentiment evolved from subscription to listing.
Symbiotec Pharmalab IPO raised ₹1757 Cr. through its IPO at a price band of ₹938 to ₹988 per share, with a lot size of 15 shares. The IPO was open for subscription from 24 Aug 2026 to 27 Aug 2026.
Researched & reviewed by
Abhishek Vohera,
Founder, IPO Guru
Last updated
Figures sourced from the RHP, BSE & NSE
GMP trend
Grey market premium sampled three times a day (11 AM, 5 PM, 10 PM). Last updated 8 Sep, 1:37 PM IST.
Day-wise GMP
The last reading of each day, newest first. Arrows compare with the previous day.
| Date | GMP | ↑↓ | % | Kostak | Sub. Sauda |
|---|---|---|---|---|---|
| 01 Sep 2026 | ₹ 185 | — | 18.72% | — | — |
| 31 Aug 2026 | ₹ 185 | ▼ | 18.72% | — | — |
| 30 Aug 2026 | ₹ 240 | — | 24.29% | — | — |
| 29 Aug 2026 | ₹ 240 | ▼ | 24.29% | — | — |
| 28 Aug 2026 | ₹ 265 | ▼ | 26.82% | — | — |
| 27 Aug 2026 | ₹ 270 | ▼ | 27.33% | — | — |
| 26 Aug 2026 | ₹ 295 | ▼ | 29.86% | — | — |
| 25 Aug 2026 | ₹ 352 | ▲ | 35.63% | — | — |
| 24 Aug 2026 | ₹ 335 | ▼ | 33.91% | — | — |
| 23 Aug 2026 | ₹ 409 | ▼ | 41.40% | — | — |
| 22 Aug 2026 | ₹ 410 | ▲ | 41.50% | — | — |
| 21 Aug 2026 | ₹ 345 | ▲ | 34.92% | — | — |
| 20 Aug 2026 | ₹ 300 | ▲ | 30.36% | — | — |
| 19 Aug 2026 | ₹ 220 | — | 22.27% | — | — |
Symbiotec Pharmalab IPO dates
Key dates from opening to listing. Today is 4 October.
- Open 24 Aug 2026
- Close 27 Aug 2026
- Allotment 28 Aug 2026
- Refund/credit 31 Aug 2026
- Listing 01 Sep 2026
Symbiotec Pharmalab IPO actual listing price
How the grey market's final call compared with the listing-day open.
| Issue price | ₹988 |
|---|---|
| GMP-based estimate (pre-listing) | ₹1173 (+18.7%) |
| Listing gain / loss | +₹0 per share |
| Listing date | 01 Sep, 2026 |
| Actual listing price | ₹988 (+0%) |
Is Symbiotec Pharmalab IPO GMP reliable?
Grey market premium for Symbiotec Pharmalab IPO should be interpreted with caution. The GMP is an unregulated, unofficial market not governed by SEBI. Here's how to read the current signal:
- 01Subscription rate matters: A high GMP paired with strong subscription — especially QIB (Qualified Institutional Buyer) oversubscription — is a more reliable bullish signal than GMP alone. Read our in-depth analysis: GMP vs Subscription Data — Which Predicts Listing Gains Better?
- 02Timing matters: GMP in the first 1–2 days of subscription is less reliable. GMP on the final subscription day and the day before listing tends to be the most accurate predictor.
- 03Grey market is thin: For smaller IPOs, even a handful of large orders can swing the GMP significantly. Treat low-volume GMP signals with extra caution.
- 04Cross-check before acting: Review the Symbiotec Pharmalab IPO full review for a fundamentals-based assessment before making any grey market trades.
Symbiotec Pharmalab IPO Kostak rate explained
Two ways the grey market trades an IPO application before listing.
The Kostak rate for Symbiotec Pharmalab IPO was not available during the subscription period. Kostak is the fixed amount a grey market buyer pays for an IPO application regardless of allotment outcome.
The Subject to Sauda price was not available for this IPO. Subject to Sauda only applies if allotment is confirmed — the buyer pays a premium on top of the issue price per lot allotted.
Grey market trading is unofficial and unregulated by SEBI. Proceed with full awareness of the associated risks.
About Symbiotec Pharmalab IPO
Symbiotec Pharmalab Ltd was set up in 2002. It is a pharmaceutical and biotechnology company that develops and makes active pharmaceutical ingredients, known as APIs, along with nutritional ingredients and specialty products. APIs are the actual medicine content that goes into a tablet or injection, which other pharma companies then turn into finished medicines.
The company started in 1995 as a small lab scale maker of steroidal hormone APIs and has grown into a large backward integrated manufacturer with more than 30 years of experience in the field. It is a global leader in corticosteroid and steroidal hormone APIs.
Its plants are approved by the United States Food and Drug Administration, by European Union Good Manufacturing Practices and by the Ministry of Food and Drug Safety of Korea, among other regulators. As on 30 June 2025 it ran two industrial scale API plants with a chemical synthesis capacity of 584.67 metric tonnes and a fermentation capacity of 300 kilolitres. It sells both in India and abroad, in regulated as well as emerging markets.
Frequently asked
What is the GMP of Symbiotec Pharmalab IPO?
The current Grey Market Premium (GMP) of Symbiotec Pharmalab IPO is ₹ 185.
What is the Kostak Price of Symbiotec Pharmalab IPO?
Kostak rate is the profit made by selling an IPO application before allotment. The current Kostak rate for Symbiotec Pharmalab IPO is not available.
What is the Subject to Sauda Price of Symbiotec Pharmalab IPO?
Subject to Sauda is the premium amount decided if the allotment is confirmed. The current Subject to Sauda rate is not available.
What was the actual listing price of Symbiotec Pharmalab IPO?
Symbiotec Pharmalab IPO listed on September 1, 2026 at ₹988, against the issue price of ₹988 — a gain of +0%.
How did the GMP of Symbiotec Pharmalab IPO trend before listing?
The GMP of Symbiotec Pharmalab IPO was stable in its final days before listing. The GMP peaked at ₹410 on 22 August 2026. View the day-wise table above for the complete GMP history.
Explore Symbiotec Pharmalab IPO further
The grey market is one signal. Read it alongside the demand, the reviews and the filings before you decide.
It has listed — go back to the fundamentals.
Category-wise demand from QIB, NII and retail investors, updated through the day.
What brokers and analysts are saying about this issue, in one place.
Check with your PAN whether shares were credited to your demat account.
The grey market called it. Now check the fundamentals.
IPO Guru tracks GMP, subscription and allotment for every Mainboard and SME issue. Read the grey market alongside the subscription book and the offer document before you apply.
Not investment advice. Grey market premium is an unofficial, unregulated indicator and is not a forecast.
